Schwannoma

Schwannomas, also known as neurilemomas, are benign tumors that arise from Schwann cells, which are responsible for forming the myelin sheath around peripheral nerves. Alfa Cytology is committed to pioneering new therapeutic approaches for schwannoma treatment for our clients.

Introduction to Schwannoma

The incidence of schwannomas is estimated to be approximately 1 per 100,000 individuals, with the majority occurring in adults between the ages of 40 and 60. The most recognized type of schwannoma is vestibular schwannoma (VS), which affects the vestibular nerve and can lead to hearing loss, tinnitus, and balance issues.

Approximately 5-10% of VS cases are bilateral, particularly in patients with neurofibromatosis type 2 (NF2), a genetic disorder characterized by the development of multiple tumors. The NF2 gene, located on chromosome 22, plays a critical role in regulating cell growth and proliferation, and its mutation is a key factor in the pathogenesis of these tumors.

Therapeutic Development for Schwannoma

As with other primary and metastatic brain tumors, the future of immune-based therapeutic approaches to meningiomas remains promising. The treatment landscape for schwannomas has evolved significantly over the past few decades. Historically, management included surgical resection, which remains the most definitive treatment for symptomatic tumors. However, surgical approaches may not always be feasible, especially in cases where tumors are large or located near critical structures. Recent advancements have focused on non-surgical interventions, particularly targeted therapies.

Our Services

At Alfa Cytology, we specialize in preclinical services tailored to the unique needs of clients working in the field of schwannoma and other oncological research. Our offerings include:

• Small Molecule Drug
• Radionuclide Therapy
• Therapeutic Antibody
• Peptide Drug

• Cell Therapy
• Gene Therapy
• Oncolytic Virotherapy
• Vaccine

Therapeutics Development

• Cell Line Development
• Organoids and Organ Chip Models
• Blood Brain Barrier Models

• Xenograft Models
• Syngeneic Models
• Virus-induced Models
• Transgenic Models
• Metastatic Models

Modeling Services

• In Vitro Efficacy Evaluation
• In Vivo Efficacy Evaluation
• In Vitro ADME

• In Vivo PK
• Safety Assessment

Preclinical Research

• Omics Analysis
• Cell Analysis
• Tissue Analysis
• Cytokine Analysis

• Growth Factor Analysis
• Primary Immune Cell Analysis

Diagnostic Development

Contact Us

For more information about our services or to discuss potential collaborations in the field of schwannoma research, please feel free to contact us.